MAR vs PFE: Which Is the Better Buy?
Side-by-side comparison of Marriott International, Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-20.
Marriott International, Inc. · Consumer Cyclical
$366.24
-3.4% upside to fair value
Med Conviction
Grade C
VS
Pfizer Inc. · Healthcare
$25.22
+2.8% upside to fair value
Grade B
QuantHub Verdict
PFE has more upside to fair value
(+2.8%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
MAR |
PFE |
| Current Price |
$366.24 |
$25.22 |
| Fair Value Estimate |
$353.64 |
$25.92 |
| Upside to Fair Value |
-3.4%
|
+2.8%
|
| Market Cap |
$96.6B |
$143.7B |
| Forward P/E |
—
|
19.2x
|
| EV / EBITDA |
23.8x
|
12.3x
|
| Price / Sales |
3.7x
|
2.3x
|
| Price / FCF |
31.6x
|
15.2x
|
| Revenue Growth YoY |
+6.2%
|
+5.4%
|
| Gross Margin |
21.4%
|
69.3%
|
| Operating Margin |
16.0%
|
23.4%
|
| Return on Equity |
-74.1%
|
8.4%
|
| Dividend Yield |
0.75% |
0% |
| FCF Yield |
3.17%
|
6.6%
|
| Analyst Consensus |
Hold
|
Hold
|
Investment Thesis
Marriott International is a global asset-light hotel franchisor, manager and licensor whose high-quality brands, nearly 283 million Bonvoy members, more than 9,900 properties across 146 countries and record 4,107-property development pipeline create meaningful network, distribution and brand advantages. Q1 2026 demonstrated resilient underlying fee economics: adjusted revenue excluding cost-reimb…
Pfizer Inc. is a leading global biopharmaceutical company with a diversified portfolio dominated by its Biopharma prescription segment, which accounts for over 90% of revenue. The company benefits from a substantial scale, a broad product portfolio including top-selling drugs like Eliquis, Prevnar, and Paxlovid, and a strong manufacturing footprint. However, Pfizer faces challenges from declining…
Accumulation Zones
| Metric |
MAR |
PFE |
| Zone Low |
$265.23 |
$19.44 |
| Zone High |
$300.59 |
$22.03 |
| In Buy Zone? |
No
|
No
|